COIOSDeep risk insights through multi-disciplinary research across the globe
white concrete building during daytime
Item confirms Peer-reviewed Added

Most people with HIV starting fostemsavir were still taking it a year later

A retrospective cohort of 77 adults starting fostemsavir in US clinical practice found most still taking it at 12 months, and most of those already suppressed stayed suppressed.

Seventy-seven adults starting fostemsavir in US clinical practice between July 2020 and August 2023 were followed for 12 months, stratified by viral suppression at baseline. Most remained on the drug at 12 months; most suppressed initiators maintained suppression, whereas only a minority of viraemic initiators achieved it. CD4 counts rose in both subgroups, with greater gains among those suppressed at initiation.

Why it is interesting: A real-world persistence and suppression reading for a late-line HIV agent in a small cohort.

Source
HIV Medicine, 22 September 2026
Paper
Real-world use and effectiveness of fostemsavir in a US clinical setting: Insights from Trio Health HIV Research Network
Authors
Elion R, Henegar C, McEwen I, Frick A, Ramgopal M, Santiago S et al.
DOI
10.1111/hiv.70303
Type
Peer-reviewed article
Design
Retrospective cohort of 77 adults initiating fostemsavir in US clinical practice, July 2020–August 2023, followed 12 months
Verdict
Confirms prior evidence
Driver
Adherence and persistence
Free full text
Free to read at the publisher

Other drivers in Behavioural science